Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway

Published:2015-10 Issue:5 Volume:24 Page:548-555
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Wilks Sharon T.

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference94 articles.

1. Untangling the ErbB signalling network;Yarden;Nat Rev Mol Cell Biol,2001

2. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

3. Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment;Hubalek;Wien Klin Wochenschr,2010

4. Race, breast cancer subtypes, and survival in the Carolina breast cancer study;Carey;JAMA,2006

5. Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen;Moon;J Cancer Res Clin Oncol,2011

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy;European Journal of Medicinal Chemistry;2024-10

2. Enhancing Antitumor Activity of Herceptin in HER2-Positive Breast Cancer Cells: A Novel DNMT-1 Inhibitor Approach;2024-09-02

3. Anticancer Activity of HER2-targeting CPP-PTEN-THP Chimeric Proteins;Anticancer Research;2024-05-31

4. IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy;Clinical Cancer Research;2024-04-05

5. The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances;Cell Biochemistry and Function;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3